{"id":5385,"date":"2026-04-15T22:41:45","date_gmt":"2026-04-15T22:41:45","guid":{"rendered":"https:\/\/entrogen.com\/web4\/?p=5385"},"modified":"2026-04-15T22:41:47","modified_gmt":"2026-04-15T22:41:47","slug":"entrogen-launches-dpyd-genotyping-kit","status":"publish","type":"post","link":"https:\/\/entrogen.com\/web4\/entrogen-launches-dpyd-genotyping-kit\/","title":{"rendered":"EntroGen Launches DPYD Genotyping Kit"},"content":{"rendered":"\n[et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; hover_enabled=&#8221;0&#8243; global_colors_info=&#8221;{}&#8221; sticky_enabled=&#8221;0&#8243;]<p>EntroGen, Inc., a leading provider of molecular diagnostic solutions in oncology, announced the launch of its <strong><a href=\"https:\/\/entrogen.com\/web4\/product\/dpyd-genotyping-kit\/\">DPYD Genotyping Kit (RUO)<\/a><\/strong> \u2014 a multiplex real-time PCR assay designed to enable rapid and reliable detection of clinically relevant DPYD germline variants associated with fluoropyrimidine toxicity.<\/p>\n<p>Recent National Comprehensive Cancer Network (NCCN) updates to clinical and regulatory guidance have emphasized the importance of DPYD testing. The U.S. Food and Drug Administration (FDA) has added boxed warnings to fluoropyrimidine drug labels recommending testing for DPYD variants prior to treatment. Additionally, the Association for Molecular Pathology (AMP), in collaboration with several organizations published recommendations that provide guidance for which DPYD variants should be tested for. The EntroGen DPYD Genotyping Kit is designed to detect high-impact Tier 1 DPYD variants recommended by AMP. These markers have been identified as essential targets due to their functional impact and population prevalence.<\/p>\n<p>Designed for flexibility and ease of adoption, the kit is compatible with widely used real-time PCR platforms. This allows laboratories to integrate DPYD testing into existing workflows without the need for specialized equipment or complex data analysis. The growing clinical adoption of DPYD testing, along with established reimbursement pathways in the United States, further supports its integration into routine laboratory workflows.<\/p>\n<p>\u201cFluoropyrimidine toxicity remains a significant and often preventable challenge in oncology,\u201d said Matthew Minkovsky, CEO of EntroGen. \u201cWith our DPYD Genotyping Kit, we focused on delivering a solution that targets the most meaningful variants while maintaining the simplicity, speed, and accessibility that laboratories expect from qPCR-based testing.\u201d<\/p>\n<p>The DPYD Genotyping Kit is now available directly from EntroGen and through its global network of authorized distributors.<\/p>\n<p data-start=\"1772\" data-end=\"1963\" class=\"\"><u><a href=\"https:\/\/entrogen.com\/web4\/product-information-request-form\/\"> <\/a><a href=\"https:\/\/entrogen.com\/web4\/product-information-request-form\/\" class=\"su-button su-button-style-default\" style=\"color: #ffffff; background-color: #2d89ef; border-color: #246ec0; border-radius: 5px;\" target=\"_blank\" rel=\"noopener noreferrer\"><span style=\"color: #ffffff; padding: 0px 16px; font-size: 13px; line-height: 26px; border-color: #6cadf4; border-radius: 5px; text-shadow: none;\"> Learn More<\/span><\/a> <\/u><\/p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]\n","protected":false},"excerpt":{"rendered":"<p>EntroGen, Inc., a leading provider of molecular diagnostic solutions in oncology, announced the launch of its DPYD Genotyping Kit (RUO) \u2014 a multiplex real-time PCR assay designed to enable rapid and reliable detection of clinically relevant DPYD germline variants associated with fluoropyrimidine toxicity. Recent National Comprehensive Cancer Network (NCCN) updates to clinical and regulatory guidance [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_uf_show_specific_survey":0,"_uf_disable_surveys":false,"footnotes":""},"categories":[3],"tags":[],"class_list":["post-5385","post","type-post","status-publish","format-standard","hentry","category-news-events"],"_links":{"self":[{"href":"https:\/\/entrogen.com\/web4\/wp-json\/wp\/v2\/posts\/5385","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/entrogen.com\/web4\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/entrogen.com\/web4\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/entrogen.com\/web4\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/entrogen.com\/web4\/wp-json\/wp\/v2\/comments?post=5385"}],"version-history":[{"count":3,"href":"https:\/\/entrogen.com\/web4\/wp-json\/wp\/v2\/posts\/5385\/revisions"}],"predecessor-version":[{"id":5389,"href":"https:\/\/entrogen.com\/web4\/wp-json\/wp\/v2\/posts\/5385\/revisions\/5389"}],"wp:attachment":[{"href":"https:\/\/entrogen.com\/web4\/wp-json\/wp\/v2\/media?parent=5385"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/entrogen.com\/web4\/wp-json\/wp\/v2\/categories?post=5385"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/entrogen.com\/web4\/wp-json\/wp\/v2\/tags?post=5385"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}